Ljiljana Kos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ljiljana Kos has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Slobodan Obradovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
7 shared publications - Boris Dzudovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
6 shared publications - Jovan Matijasevic
Clinic for Intensive Care Medicine and Pulmonary Vascular Diseases, Institute for Pulmonary Diseases Vojvodina, 21204 Sremska Kamenica, Serbia
6 shared publications - Sonja Šalinger-Martinović
Clinic of Cardiology, Clinical Center Nis, 18000 Nis, Serbia
6 shared publications - Tamara Kovacevic-Preradovic
Department of Cardiology, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
6 shared publications - Aleksandar Neskovic
Clinic of Cardiology, University Clinical Center Zemun, 11080 Belgrade, Serbia
5 shared publications
Latest Publications
- Open Access
Development of the OncoScore: A Diagnostic Prediction Score for Previously Unrecognized Malignancy in Patients with Acute Pulmonary Embolism
Background/Objectives: Pulmonary embolism (PE) may represent the first clinical manifestation of a previously unrecognized malignancy. We aimed to develop the OncoScore, a diagnostic prediction score for estimating the probability of previously unrecognized malignancy being diagnosed during the index hospitalization for acute PE. Methods: We conducted a retrospective diagnostic prediction model derivation study using prospectively collected data from the multicenter Regional Pulmonary Embolism Registry (REPER). Candidate predictors were assessed using logistic regression and Chi-square Automatic Interaction Detection (CHAID) analysis, and independent predictors were incorporated into the OncoScore. Discrimination was assessed by receiver operating characteristic (ROC) analysis, calibration by calibration slope and a calibration plot, and internal validation by bootstrap resampling. Diagnostic performance measures were calculated using the cut-off value determined by the Youden index. Results: Among 2615 patients with acute PE, 91 had newly diagnosed malignancy, 265 had previously known malignancy, and 2259 had no malignancy. The final OncoScore included hemoglobin, C-reactive protein, platelet count, and leukocyte count, with a total score ranging from 0 to 7 points. The OncoScore yielded an area under the curve (AUC) of 0.702 (95% confidence interval [CI] 0.653–0.751; p < 0.001). Bootstrap internal validation of the fixed score yielded an optimism-corrected AUC of 0.7013 and an optimism-corrected calibration slope of 1.015. When predictor selection and CHAID cut-point determination were repeated within the bootstrap procedure, the optimism-corrected AUC was 0.6560. Patients were stratified as low (≤2), intermediate (3–4), and high risk (≥5), with observed malignancy prevalences of 1.1%, 5.5%, and 10.8%, respectively. At a cut-off of ≥3 points, sensitivity was 87.5%, specificity 46.5%, positive predictive value 6.4%, and negative predictive value 98.9%. Conclusions: The OncoScore is a simple laboratory-based prediction tool that showed moderate discrimination and identified clinically distinct risk strata for malignancy diagnosed during the index hospitalization for acute PE. The score should be considered a preliminary derivation-stage model, and independent external validation is required before clinical implementation.
Open AccessDevelopment of the OncoScore: A Diagnostic Prediction Score for Previously Unrecognized Malignancy in Patients with Acute Pulmonary Embolism
Background/Objectives: Pulmonary embolism (PE) may represent the first clinical manifestation of a previously unrecognized malignancy. We aimed to develop the OncoScore, a diagnostic prediction score for estimating the probability of previously unrecognized malignancy being diagnosed during the index hospitalization for acute PE. Methods: We conducted a retrospective diagnostic prediction model derivation study using prospectively collected data from the multicenter Regional Pulmonary Embolism Registry (REPER). Candidate predictors were assessed using logistic regression and Chi-square Automatic Interaction Detection (CHAID) analysis, and independent predictors were incorporated into the OncoScore. Discrimination was assessed by receiver operating characteristic (ROC) analysis, calibration by calibration slope and a calibration plot, and internal validation by bootstrap resampling. Diagnostic performance measures were calculated using the cut-off value determined by the Youden index. Results: Among 2615 patients with acute PE, 91 had newly diagnosed malignancy, 265 had previously known malignancy, and 2259 had no malignancy. The final OncoScore included hemoglobin, C-reactive protein, platelet count, and leukocyte count, with a total score ranging from 0 to 7 points. The OncoScore yielded an area under the curve (AUC) of 0.702 (95% confidence interval [CI] 0.653–0.751; p < 0.001). Bootstrap internal validation of the fixed score yielded an optimism-corrected AUC of 0.7013 and an optimism-corrected calibration slope of 1.015. When predictor selection and CHAID cut-point determination were repeated within the bootstrap procedure, the optimism-corrected AUC was 0.6560. Patients were stratified as low (≤2), intermediate (3–4), and high risk (≥5), with observed malignancy prevalences of 1.1%, 5.5%, and 10.8%, respectively. At a cut-off of ≥3 points, sensitivity was 87.5%, specificity 46.5%, positive predictive value 6.4%, and negative predictive value 98.9%. Conclusions: The OncoScore is a simple laboratory-based prediction tool that showed moderate discrimination and identified clinically distinct risk strata for malignancy diagnosed during the index hospitalization for acute PE. The score should be considered a preliminary derivation-stage model, and independent external validation is required before clinical implementation.
- Open Access
- 10 September 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Sex-related differences in echocardiography parameters for predicting in-hospital mortality in patients with acute pulmonary embolism
Background: Risk stratification of acute pulmonary embolism (PE) is primarily based on systolic arterial pressure, right ventricular (RV) function, and cardiac troponin levels. Objectives: To investigate sex-related differences in simple RV echocardiographic parameters for predicting all-cause in-hospital mortality in acute PE. Design: Multicenter, observational, retrospective, registry-based cohort study. Methods: We analyzed data from the Regional Pulmonary Embolism Registry, including consecutive patients with acute PE confirmed by computed tomography pulmonary angiography between January 2015 and January 2026. Of 2776 patients, 2408 had at least one RV echocardiographic parameter measured at admission (RV diastolic diameter, RV systolic pressure, tricuspid annular plane systolic excursion [TAPSE], and ratio TAPSE/RV systolic pressure). Multivariable Cox regression adjusted for age, sex-specific differences, and shock at admission (systolic arterial pressure 16 mm for men, enabling discrimination between low- and high-risk patients. Mortality was 10.2% versus 0.9% in women (≤19 vs. >19 mm, p16 mm, p=0.001). In women, TAPSE >19 mm identified a subgroup with very low in-hospital mortality (1.4%) and an excellent negative predictive value (98.6%). Conclusion: In patients with acute PE, TAPSE measured at admission in women, but not in men, was the only echocardiographic parameter independently associated with all-cause in-hospital mortality.
- 10 September 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Open AccessSex-related differences in echocardiography parameters for predicting in-hospital mortality in patients with acute pulmonary embolism
Background: Risk stratification of acute pulmonary embolism (PE) is primarily based on systolic arterial pressure, right ventricular (RV) function, and cardiac troponin levels. Objectives: To investigate sex-related differences in simple RV echocardiographic parameters for predicting all-cause in-hospital mortality in acute PE. Design: Multicenter, observational, retrospective, registry-based cohort study. Methods: We analyzed data from the Regional Pulmonary Embolism Registry, including consecutive patients with acute PE confirmed by computed tomography pulmonary angiography between January 2015 and January 2026. Of 2776 patients, 2408 had at least one RV echocardiographic parameter measured at admission (RV diastolic diameter, RV systolic pressure, tricuspid annular plane systolic excursion [TAPSE], and ratio TAPSE/RV systolic pressure). Multivariable Cox regression adjusted for age, sex-specific differences, and shock at admission (systolic arterial pressure 16 mm for men, enabling discrimination between low- and high-risk patients. Mortality was 10.2% versus 0.9% in women (≤19 vs. >19 mm, p16 mm, p=0.001). In women, TAPSE >19 mm identified a subgroup with very low in-hospital mortality (1.4%) and an excellent negative predictive value (98.6%). Conclusion: In patients with acute PE, TAPSE measured at admission in women, but not in men, was the only echocardiographic parameter independently associated with all-cause in-hospital mortality.
- Open Access
Prognostic Significance of Echocardiography-Visualized Thrombus in Right Heart in Early Stages of Acute PE: 100 Patients from Regional Pulmonary Embolism Registry
Background: The significance of imaging right-heart thrombus via echocardiography in acute pulmonary embolism (PE) patients, as well as its management, remains uncertain. Methods: In this retrospective, observational, multicenter, and multinational registry of consecutive acute PE patients, we compared 100 patients in whom thrombus was visualized in the right heart during echocardiographic evaluation with 2635 patients without visualization of thrombus. The co-primary endpoints were all-cause in-hospital mortality and PE-related mortality. Secondary endpoints included the prevalence of severe PE at admission (intermediate–high and high-risk PE), the frequency of thrombolytic therapy administration, and mortality among patients who received thrombolysis. Results: All-cause and PE-related mortality were higher in patients with thrombus in the right heart (31.0% vs. 9.6%, and 25.8% vs. 5.6%, p < 0.001, respectively). Patients with right-heart thrombi had a more severe PE presentation than those without (74.0% vs. 45.3%, p < 0.001). In patients treated with thrombolysis, all-cause mortality was higher in patients with right-heart thrombi (35.5% vs. 12.7%, p < 0.001). In the multivariable Cox regression analysis adjusted for ESC mortality risk, age, presence of syncope, atrial fibrillation, and hypoxemia, patients with thrombus in the right heart had a significantly higher risk of all-cause and PE-related death compared to patients without thrombus (HR 2.60, 95% CI 1.753–3.859, p < 0.001, and HR 3.287, 95% CI 2.056–5.253, p < 0.001, respectively). Conclusions: Visualization of thrombus in transit through the right heart is associated with higher all-cause and PE-related mortality, independent of PE severity and the use of thrombolytic therapy.
Open AccessPrognostic Significance of Echocardiography-Visualized Thrombus in Right Heart in Early Stages of Acute PE: 100 Patients from Regional Pulmonary Embolism Registry
Background: The significance of imaging right-heart thrombus via echocardiography in acute pulmonary embolism (PE) patients, as well as its management, remains uncertain. Methods: In this retrospective, observational, multicenter, and multinational registry of consecutive acute PE patients, we compared 100 patients in whom thrombus was visualized in the right heart during echocardiographic evaluation with 2635 patients without visualization of thrombus. The co-primary endpoints were all-cause in-hospital mortality and PE-related mortality. Secondary endpoints included the prevalence of severe PE at admission (intermediate–high and high-risk PE), the frequency of thrombolytic therapy administration, and mortality among patients who received thrombolysis. Results: All-cause and PE-related mortality were higher in patients with thrombus in the right heart (31.0% vs. 9.6%, and 25.8% vs. 5.6%, p < 0.001, respectively). Patients with right-heart thrombi had a more severe PE presentation than those without (74.0% vs. 45.3%, p < 0.001). In patients treated with thrombolysis, all-cause mortality was higher in patients with right-heart thrombi (35.5% vs. 12.7%, p < 0.001). In the multivariable Cox regression analysis adjusted for ESC mortality risk, age, presence of syncope, atrial fibrillation, and hypoxemia, patients with thrombus in the right heart had a significantly higher risk of all-cause and PE-related death compared to patients without thrombus (HR 2.60, 95% CI 1.753–3.859, p < 0.001, and HR 3.287, 95% CI 2.056–5.253, p < 0.001, respectively). Conclusions: Visualization of thrombus in transit through the right heart is associated with higher all-cause and PE-related mortality, independent of PE severity and the use of thrombolytic therapy.
- Open Access
- 10 September 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (3) , 183
Renal Failure and Systolic Heart Failure Have Synergistic Effect on In-Hospital All-Cause Mortality in Patients with Normotensive Acute Pulmonary Embolism
Background/Objectives: Renal failure (RF) and systolic heart failure (sHF) are very often associated with each other, and their synergistic influence can affect the prognosis of acute pulmonary embolism (aPE) patients. The aim of this study is to evaluate the associations between RF, sHF, and in-hospital mortality in patients with normotensive aPE. Methods: We analyzed data from the Regional PE Registry (REPER), and 1968 patients with CT pulmonary angiography-confirmed aPE who had a systolic blood pressure of 100 mmHg and higher, and for whom creatinine blood levels and left ventricular ejection fraction (LVEF) were measured at admission to hospital were enrolled. The patients were divided into four groups: the first group comprised patients without renal and systolic heart failure, the second those with RF (creatinine clearance less than 60 mL/min), the third those with sHF (LVEF less than 50%), and the fourth those with both RF and sHF. The primary endpoint of this study was in-hospital all-cause mortality. Results: There are significant differences between in-hospital mortality among the groups: 38/1247 (3.0%) vs. 63/514 (12.9%) vs. 10/99 (10.1%) vs. 20/108 (18.5%) (p < 0.001). In the multivariable regression model adjusted for age, right ventricular dysfunction, and troponin levels, the presence of renal failure, sHF, and both were independently associated with in-hospital all-cause mortality with ORs of 3.59 (95%CI 2.04–6.30, p < 0.001) vs. 3.97 (1.71–9.25, p = 0.001) vs. 6.39 (3.15–12.99, p < 0.001), respectively. Conclusions: The association of renal failure and systolic heart failure has a deleterious prognosis in patients with normotensive aPE.
- 10 September 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (3) , 183
Open AccessRenal Failure and Systolic Heart Failure Have Synergistic Effect on In-Hospital All-Cause Mortality in Patients with Normotensive Acute Pulmonary Embolism
Background/Objectives: Renal failure (RF) and systolic heart failure (sHF) are very often associated with each other, and their synergistic influence can affect the prognosis of acute pulmonary embolism (aPE) patients. The aim of this study is to evaluate the associations between RF, sHF, and in-hospital mortality in patients with normotensive aPE. Methods: We analyzed data from the Regional PE Registry (REPER), and 1968 patients with CT pulmonary angiography-confirmed aPE who had a systolic blood pressure of 100 mmHg and higher, and for whom creatinine blood levels and left ventricular ejection fraction (LVEF) were measured at admission to hospital were enrolled. The patients were divided into four groups: the first group comprised patients without renal and systolic heart failure, the second those with RF (creatinine clearance less than 60 mL/min), the third those with sHF (LVEF less than 50%), and the fourth those with both RF and sHF. The primary endpoint of this study was in-hospital all-cause mortality. Results: There are significant differences between in-hospital mortality among the groups: 38/1247 (3.0%) vs. 63/514 (12.9%) vs. 10/99 (10.1%) vs. 20/108 (18.5%) (p < 0.001). In the multivariable regression model adjusted for age, right ventricular dysfunction, and troponin levels, the presence of renal failure, sHF, and both were independently associated with in-hospital all-cause mortality with ORs of 3.59 (95%CI 2.04–6.30, p < 0.001) vs. 3.97 (1.71–9.25, p = 0.001) vs. 6.39 (3.15–12.99, p < 0.001), respectively. Conclusions: The association of renal failure and systolic heart failure has a deleterious prognosis in patients with normotensive aPE.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 44 (4) , 15-17
Thrombus entrapped in a patent foramen ovale
Background. Patent foramen ovales are very common in the population. Thrombus entrapped in a patent foramen ovale is very rare and can cause paradoxical embolism with a high mortality rate. We present the case of a patient diagnosed with a massive pulmonary embolism and a huge thrombus stuck over the interatrial septum. Case presentation. An 83-year-old female patient was admitted to our Coronary care unit with the diagnosis of massive pulmonary embolism confirmed by contrast-enhanced chest CT scan. At admission, the patient complained of chest pain and shortness of breath for the last 24 hours. Transthoracic echocardiography (TTE) showed the presence of a thrombus entrapped in a patent foramen ovale and floating in both atria. Transesophageal echocardiography was done as well to confirm the diagnosis. Deep vein thrombosis was diagnosed by duplex ultrasonography. After discussing the risks and benefits of surgical versus medical treatment, the patient was treated with unfractionated heparin during hospitalization and rivaroxaban on discharge. Seven days later, follow-up TTE showed no clot in the heart. Conclusion. Although rare, the thrombus stuck in patent foramen ovale presents a clinical emergency so early diagnosis and treatment is mandatory.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 44 (4) , 15-17
Open AccessThrombus entrapped in a patent foramen ovale
Background. Patent foramen ovales are very common in the population. Thrombus entrapped in a patent foramen ovale is very rare and can cause paradoxical embolism with a high mortality rate. We present the case of a patient diagnosed with a massive pulmonary embolism and a huge thrombus stuck over the interatrial septum. Case presentation. An 83-year-old female patient was admitted to our Coronary care unit with the diagnosis of massive pulmonary embolism confirmed by contrast-enhanced chest CT scan. At admission, the patient complained of chest pain and shortness of breath for the last 24 hours. Transthoracic echocardiography (TTE) showed the presence of a thrombus entrapped in a patent foramen ovale and floating in both atria. Transesophageal echocardiography was done as well to confirm the diagnosis. Deep vein thrombosis was diagnosed by duplex ultrasonography. After discussing the risks and benefits of surgical versus medical treatment, the patient was treated with unfractionated heparin during hospitalization and rivaroxaban on discharge. Seven days later, follow-up TTE showed no clot in the heart. Conclusion. Although rare, the thrombus stuck in patent foramen ovale presents a clinical emergency so early diagnosis and treatment is mandatory.
- Open Access
- 1 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 24 (3) , 199-205
Prognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.
- 1 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 24 (3) , 199-205
Open AccessPrognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.
- Open Access
- 23 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (11) , 1829
New-Onset Paroxysmal Atrial Fibrillation in the Setting of Acute Pulmonary Embolism Is Associated with All-Cause Hospital Mortality in Women but Not in Men
Background: Patients with acute pulmonary embolism (PE) may have various types of atrial fibrillation (AF). The role of AF in hemodynamic states and outcomes may differ between men and women. Methods: In total, 1600 patients (743 males and 857 females) with acute PE were enrolled in this study. The severity of PE was assessed using the European Society of Cardiology (ESC) mortality risk model. Patients were allocated into three groups according to their electrocardiography recordings taken during hospitalization: sinus rhythm, new-onset paroxysmal AF, and persistent/permanent AF. The association between the types of AF and all-cause hospital mortality was tested using regression models and net reclassification index (NRI) and integrated discrimination index (IDI) statistics with respect to sex. Results: There were no differences between the frequencies of the types of AF between men and women: 8.1% vs. 9.1% and 7.5% vs. 7.5% (p = 0.766) for paroxysmal and persistent/permanent AF, respectively. We found that the rates of paroxysmal AF significantly increased across the mortality risk strata in both sexes. Among the types of AF, the presence of paroxysmal AF had a predictive value for all-cause hospital mortality independent of mortality risk and age in women only (adjusted HR, 2.072; 95% CI, 1.274–3.371; p = 0.003). Adding paroxysmal AF to the ESC risk model did not improve the reclassification of patient risk for the prediction of all-cause mortality, but instead enhanced the discriminative power of the existing model in women only (NRI, not significant; IDI, 0.022 (95% CI, 0.004–0.063); p = 0.013). Conclusion: The occurrence of paroxysmal AF in female patients with acute PE has predictive value for all-cause hospital mortality independent of age and mortality risk.
- 23 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (11) , 1829
Open AccessNew-Onset Paroxysmal Atrial Fibrillation in the Setting of Acute Pulmonary Embolism Is Associated with All-Cause Hospital Mortality in Women but Not in Men
Background: Patients with acute pulmonary embolism (PE) may have various types of atrial fibrillation (AF). The role of AF in hemodynamic states and outcomes may differ between men and women. Methods: In total, 1600 patients (743 males and 857 females) with acute PE were enrolled in this study. The severity of PE was assessed using the European Society of Cardiology (ESC) mortality risk model. Patients were allocated into three groups according to their electrocardiography recordings taken during hospitalization: sinus rhythm, new-onset paroxysmal AF, and persistent/permanent AF. The association between the types of AF and all-cause hospital mortality was tested using regression models and net reclassification index (NRI) and integrated discrimination index (IDI) statistics with respect to sex. Results: There were no differences between the frequencies of the types of AF between men and women: 8.1% vs. 9.1% and 7.5% vs. 7.5% (p = 0.766) for paroxysmal and persistent/permanent AF, respectively. We found that the rates of paroxysmal AF significantly increased across the mortality risk strata in both sexes. Among the types of AF, the presence of paroxysmal AF had a predictive value for all-cause hospital mortality independent of mortality risk and age in women only (adjusted HR, 2.072; 95% CI, 1.274–3.371; p = 0.003). Adding paroxysmal AF to the ESC risk model did not improve the reclassification of patient risk for the prediction of all-cause mortality, but instead enhanced the discriminative power of the existing model in women only (NRI, not significant; IDI, 0.022 (95% CI, 0.004–0.063); p = 0.013). Conclusion: The occurrence of paroxysmal AF in female patients with acute PE has predictive value for all-cause hospital mortality independent of age and mortality risk.